A current view of prostatic cancer

Research output: Contribution to journalArticle

Abstract

Carcinoma of the prostate is the third leading type of cancer in men over the age of fifty-five. This adenocarcinoma of unclear cause has a unique geographical distribution suggesting an environmental factor. Most patients present with metastatic disease, and definitive surgery or radiotherapy is curative in only ten percent of cases. The only reliable biologic marker for prostatic carcinoma is acid phosphatase. The treatment of metastatic disease remains controversial. Subjective relief of symptoms can be obtained in the majority of patients with either the use of DES or castration, but overall survival benefit is minimal. However, subsets of patients, excluding either high or low pathologic grades of tumor do appear to have survival benefit. The chemotherapy of prostatic carcinoma remains one of the most neglected areas of medical oncology, but in patients failing hormonal therapies, 20% to 30% may benefit from either single or combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalArizona Medicine
Volume38
Issue number3
StatePublished - 1981

Fingerprint

Prostatic Neoplasms
Carcinoma
Survival
Medical Oncology
Castration
Acid Phosphatase
Combination Drug Therapy
Prostate
Neoplasms
Adenocarcinoma
Radiotherapy
Biomarkers
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A current view of prostatic cancer. / Ahmann, Frederick R.

In: Arizona Medicine, Vol. 38, No. 3, 1981, p. 195-197.

Research output: Contribution to journalArticle

Ahmann, FR 1981, 'A current view of prostatic cancer', Arizona Medicine, vol. 38, no. 3, pp. 195-197.
Ahmann, Frederick R. / A current view of prostatic cancer. In: Arizona Medicine. 1981 ; Vol. 38, No. 3. pp. 195-197.
@article{7da5a793c03c4b4c98a9f65afcf84ad4,
title = "A current view of prostatic cancer",
abstract = "Carcinoma of the prostate is the third leading type of cancer in men over the age of fifty-five. This adenocarcinoma of unclear cause has a unique geographical distribution suggesting an environmental factor. Most patients present with metastatic disease, and definitive surgery or radiotherapy is curative in only ten percent of cases. The only reliable biologic marker for prostatic carcinoma is acid phosphatase. The treatment of metastatic disease remains controversial. Subjective relief of symptoms can be obtained in the majority of patients with either the use of DES or castration, but overall survival benefit is minimal. However, subsets of patients, excluding either high or low pathologic grades of tumor do appear to have survival benefit. The chemotherapy of prostatic carcinoma remains one of the most neglected areas of medical oncology, but in patients failing hormonal therapies, 20{\%} to 30{\%} may benefit from either single or combination chemotherapy.",
author = "Ahmann, {Frederick R}",
year = "1981",
language = "English (US)",
volume = "38",
pages = "195--197",
journal = "Arizona Medicine",
issn = "0004-1556",
publisher = "Arizona Medical Association",
number = "3",

}

TY - JOUR

T1 - A current view of prostatic cancer

AU - Ahmann, Frederick R

PY - 1981

Y1 - 1981

N2 - Carcinoma of the prostate is the third leading type of cancer in men over the age of fifty-five. This adenocarcinoma of unclear cause has a unique geographical distribution suggesting an environmental factor. Most patients present with metastatic disease, and definitive surgery or radiotherapy is curative in only ten percent of cases. The only reliable biologic marker for prostatic carcinoma is acid phosphatase. The treatment of metastatic disease remains controversial. Subjective relief of symptoms can be obtained in the majority of patients with either the use of DES or castration, but overall survival benefit is minimal. However, subsets of patients, excluding either high or low pathologic grades of tumor do appear to have survival benefit. The chemotherapy of prostatic carcinoma remains one of the most neglected areas of medical oncology, but in patients failing hormonal therapies, 20% to 30% may benefit from either single or combination chemotherapy.

AB - Carcinoma of the prostate is the third leading type of cancer in men over the age of fifty-five. This adenocarcinoma of unclear cause has a unique geographical distribution suggesting an environmental factor. Most patients present with metastatic disease, and definitive surgery or radiotherapy is curative in only ten percent of cases. The only reliable biologic marker for prostatic carcinoma is acid phosphatase. The treatment of metastatic disease remains controversial. Subjective relief of symptoms can be obtained in the majority of patients with either the use of DES or castration, but overall survival benefit is minimal. However, subsets of patients, excluding either high or low pathologic grades of tumor do appear to have survival benefit. The chemotherapy of prostatic carcinoma remains one of the most neglected areas of medical oncology, but in patients failing hormonal therapies, 20% to 30% may benefit from either single or combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0019831567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019831567&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 195

EP - 197

JO - Arizona Medicine

JF - Arizona Medicine

SN - 0004-1556

IS - 3

ER -